Working Group on Cancer Services
Terms of Reference

1. The College's Mission Statement
   The Royal College of Pathologists' mission is to: advance the science and practice of pathology; further public education in the field of pathology; and, promote study, research and innovation in pathology and disseminate results.

2. Purpose
   The Working Group on Cancer Services has delegated responsibility from Council through the College’s Specialty Advisory Committee (SAC) on Cellular Pathology for the following matters:
   - To commission, review and publish a series of succinct, evidence-based publications (cancer datasets) defining minimum standards for reporting of common cancers.
   - To ensure that pathological standards in the datasets are defined by histopathologists (now cellular pathologists) and that College Fellows are involved in a consultation process to agree on the standards.
   - To prevent the proliferation of diverse and possibly conflicting local guidelines.

3. Oversight Responsibilities
   - To commission the production of guidelines and datasets for the reporting of cancers, and to undertake regular reviews and updates of these in accordance with the criteria for NICE accreditation.
   - To advise on the dissemination and implementation of the guidelines and datasets.
   - To assist the College with consultations on and implementation of cancer standards with implications for pathology services.
   - To advise on procedures, standards and guidance necessary to ensure high standards of pathology in relation to cancer services.
   - To foster working relationships with other groups, e.g. the Cancer Outcomes and Services Dataset (COSD), United Kingdom and Ireland Association of Cancer Registries (UKIACR), Association of Clinical Pathologists (ACP), British Division of the International Academy of Pathology (BDIAP), International Collaboration on Cancer Reporting (ICCR).
   - Establish a dedicated line of communication/reporting to and from NHS at a national level – this would include NHS England, NHS Wales, NHS Scotland and Health and Social Care in Northern Ireland.
   - Establish a formal mechanism to link Cancer Datasets to the National Genomic Test Directory – in line with responsibility of the Group to foster working relationships with other groups.
   - To facilitate incorporation of the pathology cancer datasets into the COSD.
   - To commission the production of Tissue Pathways for the handling and reporting of non-cancer specimens.
4. Accountabilities
   - To report to the SAC on Cellular Pathology. The WGCS Chair is an ex-officio member of the SAC.

5. Approval Authority
   - The Chair is responsible of approving the minutes of the group.
   - The group is responsible for approving items and work related to the development of datasets and tissues pathways.

6. Governance
   - To report to the SAC on Cellular Pathology.
   - The Clinical Effectiveness Department is responsible for the appointment of members to the group and the continuity of representation. Vacant positions on the Group are advertised on the College website. Applicants must submit a CV and statement of interest and meet the required person specifications. Applicants are then approved by votes from existing committee members.

7. Membership
   - Members of the Group are selected by appointment for a period of three years, with the possibility of extending the term of office up to a maximum of five years.
   - The membership of the group will be College appointed members and shall be approved by Council. The membership shall comprise the following:

| Chair | Cellular pathologist with active FRCPPath College membership
|       | The Chair will be as ex-officio College representative on the International Collaboration on Cancer Reporting (ICCR) |
| Eight appointed pathologists | Cellular pathologists with active FRCPPath College membership to promote diversity of sub-specialty representation and provide resource for the ever-increasing complexity of cancer datasets and tissue pathways. One will be chosen as a second College representative on the International Collaboration on Cancer Reporting (ICCR) |
| Co-opted external representation dependent on the committee. Each committee will recommend organisations they should be collaborating with for the approval by Council. (Co-opted members will not be entitled to vote on any committee matters. The term of office is normally one year for specific areas of interest) | 1. Association of Clinical Pathologists
2. British Division of the International Academy of Pathology
3. Cancer Outcomes and Services Dataset
4. United Kingdom and Ireland Association of Cancer Registries
5. NHS Genomics/NHS England/GLH Histopathology Lead(s)
6. An external representative for the NHS at UK level to cover all four devolved NHS responsibilities |
APPENDIX

The current membership consists of the following:

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Start date</th>
<th>End of (3 years)</th>
<th>End of term (5 years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Michael Eden</td>
<td>Chair Cancer Outcomes and Services Dataset (COSD) and National Cancer Registration and Analysis (NCRAS) and International collaboration on Cancer reporting (ICCR)</td>
<td>November 2018</td>
<td></td>
<td>November 2023</td>
</tr>
<tr>
<td>Professor Keith Hunter</td>
<td>Appointed member&lt;br&gt;Currently representing and reporting three organisations</td>
<td>November 2018</td>
<td></td>
<td>November 2023</td>
</tr>
<tr>
<td>Dr Muhammad Shafiq Gill</td>
<td>Appointed member&lt;br&gt;Currently representing and reporting three organisations</td>
<td>November 2018</td>
<td></td>
<td>November 2023</td>
</tr>
<tr>
<td>Professor Sebastian Brandner</td>
<td>Appointed member&lt;br&gt;Currently representing and reporting three organisations</td>
<td>November 2019</td>
<td>November 2022</td>
<td></td>
</tr>
<tr>
<td>Dr Paul Craig</td>
<td>Co-opted representative&lt;br&gt;British Division of the International Academy of Pathology (BDIAP)</td>
<td>June 2020</td>
<td>June 2023</td>
<td></td>
</tr>
<tr>
<td>Dr Guy Martland</td>
<td>Co-opted representative&lt;br&gt;Association of Clinical Pathologists (ACP)</td>
<td>June 2021</td>
<td>June 2024</td>
<td></td>
</tr>
<tr>
<td>Dr Newton Wong</td>
<td>Appointed member&lt;br&gt;Currently representing and reporting three organisations</td>
<td>June 2021</td>
<td>June 2024</td>
<td></td>
</tr>
<tr>
<td>Professor Ian Alexander Cree</td>
<td>Co-opted representative International</td>
<td>June 2022</td>
<td>June 2025</td>
<td></td>
</tr>
</tbody>
</table>
The Royal College of Pathologists understands the value and strength that diversity brings, and we are proud to be an organisation of members from a wide range of backgrounds. We are keen to encourage and enable more people of all identities and from all backgrounds to become involved in the College.

8. Meetings

- Meetings are held twice a year, usually for 3 hours in June and November.
- Administrative support is provided by the Clinical Effectiveness Department at the College.
- The Clinical Effectiveness Department will collaborate with the Chair and keep the members informed through regular communication.
- Agendas and papers will be circulated at least one week before each meeting
- Minutes will be made available on the College website, with access restricted to College members only via myRCPPath.

Members are expected, each calendar year, to:

- Attend (in person or by video/teleconference) at least 50% of the WGCS meetings.
- Review at least 50% of the cancer datasets and tissue pathways (and other documents) that are circulated by the Chair via the Clinical Effectiveness Department and notify the Clinical Effectiveness Department lead if they are unable to carry out a review.
- Discuss/review the contributions of the group on an annual basis.

9. Resources

- Travelling expenses will be paid to members (but not observers) of the group in line with the College’s expenses policy. The expenses policy is available on the website. Claims should be made through the College’s on-line finance system.

Terms of Reference agreed at group meeting 26 January 2022
Chair of group Dr Michael Eden Signed 26/1/2022

Approved by Cellular Pathology SAC ____________________

Approved at College Council meeting ____________________

Review date (3 years following Council approval) ________________